{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:36:54Z","timestamp":1785285414146,"version":"3.55.0"},"reference-count":42,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pharmacovigilance plays a critical role in ensuring the safety of medicinal products, particularly those under additional monitoring (AM). The European Union (EU) implemented AM in 2012 to enhance post\u2010marketing surveillance. However, its impact on adverse drug reaction (ADR) reporting and pharmacists' role remains insufficiently explored. This scoping review examines the influence of AM label on ADR reporting management, and pharmacists' awareness and involvement in AM medicines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search across four scientific databases (Web of Science, Scopus, Science Direct, and PubMed) and gray literature sources, covering studies published between 2012 and 2024 in the EU, identified 17 relevant studies according to eligibility criteria: AM labeling's impact on pharmacovigilance in the EU. Relevant data (title, year of publication, country, field, design, objective, results) and relation with research questions were charted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>AM label alone does not significantly increase ADR reporting rates. However, structured training programs and targeted interventions for healthcare professionals (HCPs), particularly pharmacists, lead to improved ADR reporting and patient safety outcomes. Pharmacists exhibit the highest awareness of AM among HCPs but often underutilize their role in ADR reporting. Different studies demonstrated that pharmacist\u2010led interventions significantly increased ADR notifications. Education campaigns, standardized reporting protocols, and enhanced integration of AM into clinical practice can strengthen AM pharmacovigilance efforts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This review highlights the need to implement structured AM training programs and develop systematic evaluation frameworks to assess the effectiveness of AM labeling in improving pharmacovigilance practices. Further research is required to optimize AM strategies and reinforce pharmacists' role in post\u2010marketing drug safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pds.70201","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T09:37:26Z","timestamp":1755250646000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of Additional Monitoring on Pharmacovigilance and Pharmacists' Role: A Scoping Review"],"prefix":"10.1002","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9028-8236","authenticated-orcid":false,"given":"Xabier","family":"Aizpurua\u2010Arruti","sequence":"first","affiliation":[{"name":"Official Pharmacist Association of Gipuzkoa  Donostia, San Sebasti\u00e1n Spain"},{"name":"Pharmacy Practice Research Group, PharmaNanoGene Group, Faculty of Pharmacy, University of the Basque Country UPV\/EHU  Vitoria\u2010Gasteiz Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7990-5192","authenticated-orcid":false,"given":"Est\u00edbaliz","family":"Goyenechea","sequence":"additional","affiliation":[{"name":"Official Pharmacist Association of Gipuzkoa  Donostia, San Sebasti\u00e1n Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7575-2715","authenticated-orcid":false,"given":"Arantxa","family":"Isla","sequence":"additional","affiliation":[{"name":"Pharmacy Practice Research Group, PharmaNanoGene Group, Faculty of Pharmacy, University of the Basque Country UPV\/EHU  Vitoria\u2010Gasteiz Spain"},{"name":"Bioaraba, Microbiology, Infectious Disease, Antimicrobial Agents, and Gene Therapy  Vitoria\u2010Gasteiz Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1726-6943","authenticated-orcid":false,"given":"Ainhoa","family":"O\u00f1atibia\u2010Astibia","sequence":"additional","affiliation":[{"name":"Official Pharmacist Association of Gipuzkoa  Donostia, San Sebasti\u00e1n Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2809-6249","authenticated-orcid":false,"given":"Amaia","family":"Malet\u2010Larrea","sequence":"additional","affiliation":[{"name":"Official Pharmacist Association of Gipuzkoa  Donostia, San Sebasti\u00e1n Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1019-0234","authenticated-orcid":false,"given":"Miguel \u00c1ngel","family":"Gastelurrutia","sequence":"additional","affiliation":[{"name":"Official Pharmacist Association of Gipuzkoa  Donostia, San Sebasti\u00e1n Spain"},{"name":"Pharmaceutical Care Research Group, Faculty of Pharmacy, University of Granada  Granada Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9127-0775","authenticated-orcid":false,"given":"Mar\u00eda \u00c1ngeles","family":"Solin\u00eds","sequence":"additional","affiliation":[{"name":"Pharmacy Practice Research Group, PharmaNanoGene Group, Faculty of Pharmacy, University of the Basque Country UPV\/EHU  Vitoria\u2010Gasteiz Spain"},{"name":"Bioaraba, Microbiology, Infectious Disease, Antimicrobial Agents, and Gene Therapy  Vitoria\u2010Gasteiz Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2478-0884","authenticated-orcid":false,"given":"Ana","family":"Del Pozo\u2010Rodriguez","sequence":"additional","affiliation":[{"name":"Pharmacy Practice Research Group, PharmaNanoGene Group, Faculty of Pharmacy, University of the Basque Country UPV\/EHU  Vitoria\u2010Gasteiz Spain"},{"name":"Bioaraba, Microbiology, Infectious Disease, Antimicrobial Agents, and Gene Therapy  Vitoria\u2010Gasteiz Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620976951"},{"key":"e_1_2_10_3_1","unstructured":"\u201cRegulation (EU) No 1027\/2012 of the European Parliament and of the Council of 25 October 2012 \u201dhttps:\/\/eur\u2010lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:L:2012:316:0038:0040:EN:PDF."},{"key":"e_1_2_10_4_1","unstructured":"European Medicines Agency \u201cMedicines Under Additional Monitoring \u201dhttps:\/\/www.ema.europa.eu\/en\/human\u2010regulatory\u2010overview\/post\u2010authorisation\/pharmacovigilance\u2010post\u2010authorisation\/medicines\u2010under\u2010additional\u2010monitoring."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018\u2010200629050\u201000003"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta15200"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010014\u20100240\u20101"},{"key":"e_1_2_10_8_1","unstructured":"C.Hernandez Garc\u00eda L.Pinheiro M.\u00c1ngel Maci\u00e1 et\u00a0al. \u201cSpontaneous Adverse Drug Reactions: Subgroup Report 2018 \u201dhttps:\/\/www.ema.europa.eu\/en\/documents\/report\/spontaneousadverse\u2010drug\u2010reactions\u2010subgroup\u2010report_en.pdf."},{"key":"e_1_2_10_9_1","unstructured":"World Health Organization (WHO) \u201cThe Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products \u201d(2002) https:\/\/iris.who.int\/bitstream\/handle\/10665\/42493\/a75646.pdf."},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0180-9"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.932942"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4800"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4792"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102288\u201013\u201048"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/13645570320001196166"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.7326\/M18\u20100850"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_10_18_1","unstructured":"European Commission \u201cReport From the Commission to the European Parliament and the Council on the National and European Medicines Agency Experience Regarding the List of Medicines for Human Use Subject to Additional Monitoring \u201dhttps:\/\/eur\u2010lex.europa.eu\/legal\u2010content\/EN\/TXT\/PDF\/?uri=CELEX:52019DC0591."},{"key":"e_1_2_10_19_1","unstructured":"European Medicines Agency \u201cEuropean Medicines Agency and Member States Joint Report to the European Commission on the Experience With the List of Products Subject to Additional Monitoring \u201d(2018) https:\/\/health.ec.europa.eu\/document\/download\/0e8a930f\u20105b2a\u201045e6\u201090a1\u2010a7ce465fddeb_en."},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5174"},{"key":"e_1_2_10_21_1","unstructured":"\u201cSCOPE Work Package 4 ADR Collection. Identification Management and Raising Awareness of ADR Reports for Drugs Subject to Additional Monitoring \u201dhttps:\/\/aleidoexamples.com\/scope_training\/WP4\/Additional%20Monitoring.pdf."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5162"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/IPRP.S466129"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30040315"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1714\/2852.287799"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219849277"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1090707"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1316486"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010017\u20102223\u20105"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2019.01.007"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259\u2010018\u20100281\u20106"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare91115400"},{"key":"e_1_2_10_33_1","first-page":"A156","article-title":"Analysis of the Medicines Under Additional Monitoring Authorised in the European Union From 2017 to 2019","volume":"28","author":"Pacheco\u2010L\u00f3pez P.","year":"2021","journal-title":"European Journal of Hospital Pharmacy"},{"key":"e_1_2_10_34_1","unstructured":"European Medicines Agency \u201cGuideline on Good Pharmacovigilance Practices: Module X\u2014Additional Monitoring \u201dhttps:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/guideline\u2010good\u2010pharmacovigilance\u2010practices\u2010module\u2010x\u2010additional\u2010monitoring_en.pdf."},{"key":"e_1_2_10_35_1","unstructured":"Australian Government \u201cTherapeutic Goods Administration. The Black Triangle Scheme \u201dhttps:\/\/www.tga.gov.au\/how\u2010we\u2010regulate\/monitoring\u2010safety\u2010and\u2010shortages\/report\u2010adverse\u2010event\u2010or\u2010incident\/report\u2010adverse\u2010events\u2010medicines\u2010and\u2010biologicals\/black\u2010triangle\u2010scheme#:~:text=How%20the%20Black%20Triangle%20Scheme Product%20Information%20(PI)%20documents."},{"key":"e_1_2_10_36_1","unstructured":"UK Government \u201cThe Black Triangle Scheme \u201dhttps:\/\/www.gov.uk\/drug\u2010safety\u2010update\/the\u2010black\u2010triangle\u2010scheme\u2010or#:~:text=A%20Black%20Triangle%20symbol%20is a%20new%20route%20of%20administration."},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1746762"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010021\u201001098\u20104"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2018.809"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcsop.2025.100578"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.30827\/ars.v66i1.31316"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4966"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.30827\/ars.v66i1.31598"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T04:11:42Z","timestamp":1764562302000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.70201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/pds.70201"],"URL":"https:\/\/doi.org\/10.1002\/pds.70201","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"2025-03-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70201"}}